ClinicalTrials.gg
CompletedNCT03194867Updated Jun 14, 2024Results posted

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

A Phase 1/2 interventional study of Isatuximab SAR650984 and Cemiplimab REGN2810 in Plasma Cell Myeloma, sponsored by Sanofi. Completed at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-14.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Multiple Myeloma by Sanofi — 3 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · Sanofi.

Enrollment
10th of 34
109 · median 56
Started
2018
with 1 other
Phase 1/2
3 of 39
1 open now
Registered
25th of 39
by date

Among the 39 studies in Multiple Myeloma by Sanofi, this one is the 10th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 1/2, and was the 25th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

3 of the 39 studies in Multiple Myeloma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Multiple Myeloma by Sanofi, or all of them as a file.
02

Study summary

Primary Objectives:

  • To evaluate the safety and tolerability of the combination of isatuximab (also known as SAR650984) and cemiplimab (also known as REGN2810) in patients with relapse/refractory multiple myeloma.
  • To compare the overall response of the combination of isatuximab and cemiplimab versus isatuximab alone in patients with RRMM based on International Myeloma Working Group (IMWG) criteria.

Secondary Objectives:

  • To evaluate the efficacy as assessed by clinical benefit rate (CBR), duration of response (DOR), time to response (TTR), progression free survival (PFS), and overall survival (OS).
  • To assess the pharmacokinetics (PK) of isatuximab and cemiplimab when given in combination.
  • To assess the immunogenicity of isatuximab and cemiplimab when given in combination.
Read the detailed description

The duration of the study for a patient will include a period for screening of up to 21 days and 3-month post treatment follow up. The cycle duration is 28 days. Patients will continue treatment until disease progression, unacceptable adverse events, consent withdrawal, or any other reason.

03

Conditions studied

  • Plasma Cell Myeloma

Browse trials for

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a known diagnosis of multiple myeloma with evidence of , as defined below:

    • Serum M-protein ≥1 g/dL (≥0.5 g/dL in case of immunoglobulin A [IgA] disease), AND/OR
    • Urine M-protein ≥200 mg/24 hours, OR
    • In the absence of measurable M-protein, serum immunoglobulin free light chain ≥10 mg/dL, and abnormal serum immunoglobulin kappa lambda free light chain ratio (\<0.26 or >1.65).
  • Patients must have received prior treatment with an immunomodulatory drug (IMiD) (for ≥2 cycles or ≥2 months of treatment) and a proteasome inhibitor (PI) (for ≥2 cycles or ≥2 months of treatment).
  • Patients must have received at least 3 (Note: Induction therapy and stem cell transplant ± maintenance will be considered as one line).
  • Patient must have achieved MR or better with any anti-myeloma therapy (ie, primary disease is not eligible).

Exclusion criteria

Exclusion criteria:

  • Prior exposure to isatuximab or participated clinical studies with isatuximab.
  • Prior exposure to any agent (approved or ) that blocks the programmed cell death-1 ()/PD-L1 pathway.
  • Evidence of other immune related disease/conditions.
  • History of non-infectious pneumonitis requiring or current pneumonitis; history of the thoracic radiation.
  • Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
  • Has allogenic haemopoietic stem cell (HSC) transplant.
  • Prior treatment with idelalisib (a PI3K inhibitor).
  • (ECOG) performance status (PS) >2.
  • Poor bone marrow reserve.
  • Poor organ function.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Isatuximab/cemiplimab (Regimen 1)

    Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression. Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression.

    Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810

  • Experimental
    Isatuximab/cemiplimab (Regimen 2)

    Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression. Cemiplimab on Day 1 in 28-day cycle up to disease progression.

    Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810

  • Active comparator
    Isatuximab

    Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.

    Drug: Isatuximab SAR650984

Interventions

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

    Also known as: Sarclisa

  • Pharmaceutical form: solution for infusion Route of administration: intravenous

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)

    Potential DLTs were defined as the occurrence of any of the following adverse reactions at first treatment cycle, unless due to disease progression or obviously unrelated cause: Hematological DLTs: Grade(G) 4 neutropenia (N) for more than 7 consecutive days, G3 to G4 N complicated by fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia associated with clinically significant bleeding requiring clinical intervention or Non-hematological DLTs: G4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days despite optimal care support, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that the investigator/study committee deemed to be dose-limiting, regardless of grade, was also considered as DLT.

    Time frame: Cycle 1 Day 1 to Day 28

  2. Phase 1 and Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product and which did not necessarily have a causal relationship with study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration up to 30 days after the last dose of study treatment administration. The DLT observation period was 1 cycle (28 days). However, all AEs during treatment, unless due to disease progression or an obviously unrelated cause, were taken into consideration by the Study Committee for the determination of the maximum tolerated dose and recommended Phase 2 dose.

    Time frame: TEAEs were collected from the first dose up to 30 days after the last dose of study treatment, approximately 50 months

  3. Phase 2: Percentage of Participants With Overall Response Rate (ORR)

    ORR by Investigator using international myeloma working group (IMWG) response criteria:percentage of participants with complete response (CR) (including stringent CR \[sCR\]very good partial response \[VGPR\] and partial response \[PR\]).CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,less than (\<)5% plasma cells in bone marrow (BM) aspirates and normal free light chain(FLC)ratio (0.26-1.65).sCR:CR plus no clonal cells in BM biopsy.VGPR:serum and urine M-protein detectable by immunofixation,not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24hour(h);FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels.PR:\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or \<200mg/24h.In addition to above, if present at baseline,\>=50% reduction in size (sum of products of maximal perpendicular diameters of measured lesions \[SPD\]) of soft tissue plasmacytomas required.

    Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months

Secondary outcomes

  1. Phase 2: Percentage of Participants With Clinical Benefit Rate (CBR)

    CBR by Investigator using IMWG response criteria: percentage of participants with CR (including sCR), VGPR, PR (all defined in previous OM) or MR. MR was defined as \>= 25% but \<= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceeded 200 mg/24h; if present at baseline, \>=50% reduction in size (SPD) of soft tissue plasmacytomas was also required.

    Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months

  2. Phase 2: Duration of Follow-up

    Duration of follow-up was defined as the date of randomization to the date of last contact or death, whichever came first. Median duration of follow-up is reported.

    Time frame: From the date of randomization up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months

  3. Phase 2: Duration of Response (DOR)

    DOR: Time from date of first response (\>=PR) that was subsequently confirmed to date of first documented progressive disease (PD) or death.DOR was determined only for participants who achieved a response of PR or better.If progression or death not observed, participant was censored at date of last valid disease assessment not showing disease progression performed prior to initiating further anticancer treatment and analysis cut-off date.PD(IMWG criteria):increase of \>=25% from lowest confirmed value in any 1 of following:serum M-protein (absolute increase\>=0.5 gram/deciliter\[g/dL\]), serum M-protein increase\>=1g/dL if lowest M component \>=5g/dL; urine M-component (absolute increase \>=200mg/24h),appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in longest diameter of a previous lesion \>1cm in short axis,\>=50% increase in circulating plasma cells (minimum 200 cells/microliter\[c/mcL\]) if that was the only measure of disease. PR: as defined in OM3.

    Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months

  4. Phase 2: Time to Response (TTR)

    TTR was defined as the time from randomization to first response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 hours. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size SPD of soft tissue plasmacytomas was also required.

    Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months

  5. Phase 2: Progression Free Survival (PFS)

    PFS: Time interval from the randomization date to the date of the first documented disease progression that is subsequently confirmed or the date of death due to any cause, whichever came first. If progression or death was not observed, participant was censored at date of last valid disease assessment not showing disease progression performed prior to initiation of a further anticancer treatment or the analysis cut-off date. Analysis was performed by Kaplan-Meier method. PD (IMWG) criteria: increase of \>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase \>=0.5g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase \>=200mg/24h), appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in the longest diameter of a previous lesion \>1 cm in short axis or \>=50% increase in circulating plasma cells (minimum of 200 c/mcL) if that was the only measure of disease.

    Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months

  6. Phase 2: Overall Survival (OS)

    OS was defined as the time interval from the date of randomization to death from any cause. Participants without death prior to the analysis cut-off date were censored at the last date the participant was known to be alive or the cut-off date, whichever came first. The results provided below corresponds to descriptive OS information at the time of primary analysis completion date of 09 October 2019.

    Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months

  7. Phase 1 and 2: Plasma Concentration Observed at the End of IV Infusion (Ceoi) of Isatuximab Alone and in Combination With Cemiplimab

    Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Ceoi. It was calculated using non-compartmental analysis (NCA) after the first administration in Cycle 1. The PK population was defined independently for isatuximab and cemiplimab and consisted of all participants from the all-treated (AT) population with at least 1 available concentration post-baseline (whatever the cycle and even if dosing was incomplete) with adequate documentation of dosing and sampling dates and times.

    Time frame: At end of infusion (EOI) on Cycle 1 Day 1

  8. Phase 1 and 2: Maximum Observed Concentration (Cmax) of Isatuximab Alone and in Combination With Cemiplimab

    Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Cmax. It was calculated using NCA after the first administration in Cycle 1.

    Time frame: At start of infusion (SOI), EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1

  9. Phase 1 and 2: Time to Reach Cmax (Tmax) of Isatuximab Alone and in Combination With Cemiplimab

    Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of tmax. It was calculated using NCA after the first administration in Cycle 1.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1

  10. Phase 1 and 2: Last Concentration Observed Above the Lower Limit of Quantitation (Clast) of Isatuximab Alone and in Combination With Cemiplimab

    Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Clast. It was calculated using NCA after the first administration in Cycle 1.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1

  11. Phase 1 and 2: Time of Clast (Tlast) of Isatuximab Alone and in Combination With Cemiplimab

    Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of tlast. It was calculated using NCA after the first administration in Cycle 1.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1

  12. Phase 1 and 2: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUClast) of Isatuximab Alone and in Combination With Cemiplimab

    AUClast was defined as the area under the plasma concentration versus time curve from time 0 to real time tlast calculated using the trapezoidal method over the dosing interval after the first administration in Cycle 1.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1

  13. Phase 1 and 2: AUC From Time 0 to Week 1 (AUC1week) of Isatuximab Alone and in Combination With Cemiplimab

    AUC1week was defined as the area under the plasma concentration versus time curve from time 0 to 1 week post dose calculated using the trapezoidal method over the dosing interval after the first administration in Cycle 1.

    Time frame: At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1

  14. Phase 1 and 2: Number of Participants With Anti-Drug Antibodies (ADA) to Isatuximab

    ADA responses were categorized as treatment-induced ADA and treatment boosted ADA. Pre-existing ADA was defined as ADA that were present in samples drawn during the pre-treatment period. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. The ADA evaluable population was defined independently for isatuximab and cemiplimab and consisted of all participants from AT population with at least 1 ADA result (negative, positive, or inconclusive) post-baseline.

    Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 20 months

  15. Phase 1 and 2: Number of Participants With ADA to Cemiplimab

    ADA responses were categorized as treatment-induced ADA and treatment boosted ADA. Pre-existing ADA was defined as ADA that were present in samples drawn during the pre-treatment period. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer.

    Time frame: From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 20 months

07

Results

Posted Jun 14, 2024

Participant flow

Participants were screened at 30 sites. The study was conducted i.e. participants were randomized at 29 sites in 10 countries. A total of 3 participants in Phase 1 and 106 participants in Phase 2 were enrolled (Phase 1)/randomized (Phase 2) from 21 Feb 2018 to 20 Mar 2019.

Participant flow — Overall Study
MilestonePhase 1: Isatuximab + Cemiplimab Once Every 2 Weeks (Q2W)Phase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + Cemiplimab Once Every 4 Weeks (Q4W)
Started3343636
Randomized and treated3343536
Completed3343536
Not completed0010
Withdrew: Incorrect completion of end of study form0010

Outcome measures

PrimaryPhase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)

Potential DLTs were defined as the occurrence of any of the following adverse reactions at first treatment cycle, unless due to disease progression or obviously unrelated cause: Hematological DLTs: Grade(G) 4 neutropenia (N) for more than 7 consecutive days, G3 to G4 N complicated by fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia associated with clinically significant bleeding requiring clinical intervention or Non-hematological DLTs: G4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days despite optimal care support, delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other AE that the investigator/study committee deemed to be dose-limiting, regardless of grade, was also considered as DLT.

Time frame:
Cycle 1 Day 1 to Day 28
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
ParticipantsPhase 1: Isatuximab + CemiplimabQ2W
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)0
PrimaryPhase 1 and Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered with a pharmaceutical product and which did not necessarily have a causal relationship with study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration up to 30 days after the last dose of study treatment administration. The DLT observation period was 1 cycle (28 days). However, all AEs during treatment, unless due to disease progression or an obviously unrelated cause, were taken into consideration by the Study Committee for the determination of the maximum tolerated dose and recommended Phase 2 dose.

Time frame:
TEAEs were collected from the first dose up to 30 days after the last dose of study treatment, approximately 50 months
Reported as:
Count of participants · Participants
Phase 1 and Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPhase 1: Isatuximab + CemiplimabQ2WPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
TEAEs3333633
TESAEs1171721
PrimaryPhase 2: Percentage of Participants With Overall Response Rate (ORR)

ORR by Investigator using international myeloma working group (IMWG) response criteria:percentage of participants with complete response (CR) (including stringent CR \[sCR\]very good partial response \[VGPR\] and partial response \[PR\]).CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas,less than (\<)5% plasma cells in bone marrow (BM) aspirates and normal free light chain(FLC)ratio (0.26-1.65).sCR:CR plus no clonal cells in BM biopsy.VGPR:serum and urine M-protein detectable by immunofixation,not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24hour(h);FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels.PR:\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or \<200mg/24h.In addition to above, if present at baseline,\>=50% reduction in size (sum of products of maximal perpendicular diameters of measured lesions \[SPD\]) of soft tissue plasmacytomas required.

Time frame:
From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Overall Response Rate (ORR)
percentage of participantsPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Phase 2: Percentage of Participants With Overall Response Rate (ORR)11.8 (3.30 to 27.45)25.0 (12.12 to 42.20)22.2 (10.12 to 39.15)
SecondaryPhase 2: Percentage of Participants With Clinical Benefit Rate (CBR)

CBR by Investigator using IMWG response criteria: percentage of participants with CR (including sCR), VGPR, PR (all defined in previous OM) or MR. MR was defined as \>= 25% but \<= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceeded 200 mg/24h; if present at baseline, \>=50% reduction in size (SPD) of soft tissue plasmacytomas was also required.

Time frame:
From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With Clinical Benefit Rate (CBR)
percentage of participantsPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Phase 2: Percentage of Participants With Clinical Benefit Rate (CBR)23.5 (10.75 to 41.17)36.1 (20.82 to 53.78)38.9 (23.14 to 56.54)
SecondaryPhase 2: Duration of Follow-up

Duration of follow-up was defined as the date of randomization to the date of last contact or death, whichever came first. Median duration of follow-up is reported.

Time frame:
From the date of randomization up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Reported as:
Median · months
Phase 2: Duration of Follow-up
monthsPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Phase 2: Duration of Follow-up10.28 (8.739 to 11.368)8.84 (8.016 to 11.072)9.03 (8.016 to 10.875)
SecondaryPhase 2: Duration of Response (DOR)

DOR: Time from date of first response (\>=PR) that was subsequently confirmed to date of first documented progressive disease (PD) or death.DOR was determined only for participants who achieved a response of PR or better.If progression or death not observed, participant was censored at date of last valid disease assessment not showing disease progression performed prior to initiating further anticancer treatment and analysis cut-off date.PD(IMWG criteria):increase of \>=25% from lowest confirmed value in any 1 of following:serum M-protein (absolute increase\>=0.5 gram/deciliter\[g/dL\]), serum M-protein increase\>=1g/dL if lowest M component \>=5g/dL; urine M-component (absolute increase \>=200mg/24h),appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in longest diameter of a previous lesion \>1cm in short axis,\>=50% increase in circulating plasma cells (minimum 200 cells/microliter\[c/mcL\]) if that was the only measure of disease. PR: as defined in OM3.

Time frame:
From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Reported as:
Median · months
Phase 2: Duration of Response (DOR)
monthsPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Phase 2: Duration of Response (DOR)5.6 (4 to 7)4.7 (3 to 12)5.7 (2 to 12)
SecondaryPhase 2: Time to Response (TTR)

TTR was defined as the time from randomization to first response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>=90% or to \<200 mg/24 hours. In addition to the above listed criteria, if present at baseline, a \>=50% reduction in the size SPD of soft tissue plasmacytomas was also required.

Time frame:
From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Reported as:
Median · months
Phase 2: Time to Response (TTR)
monthsPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Phase 2: Time to Response (TTR)1.5 (1 to 2)1.0 (1 to 3)1.0 (1 to 4)
SecondaryPhase 2: Progression Free Survival (PFS)

PFS: Time interval from the randomization date to the date of the first documented disease progression that is subsequently confirmed or the date of death due to any cause, whichever came first. If progression or death was not observed, participant was censored at date of last valid disease assessment not showing disease progression performed prior to initiation of a further anticancer treatment or the analysis cut-off date. Analysis was performed by Kaplan-Meier method. PD (IMWG) criteria: increase of \>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase \>=0.5g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase \>=200mg/24h), appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in the longest diameter of a previous lesion \>1 cm in short axis or \>=50% increase in circulating plasma cells (minimum of 200 c/mcL) if that was the only measure of disease.

Time frame:
From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Reported as:
Median · months
Phase 2: Progression Free Survival (PFS)
monthsPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Phase 2: Progression Free Survival (PFS)2.89 (1.971 to 3.811)3.75 (1.971 to 5.881)3.02 (2.793 to 5.158)
SecondaryPhase 2: Overall Survival (OS)

OS was defined as the time interval from the date of randomization to death from any cause. Participants without death prior to the analysis cut-off date were censored at the last date the participant was known to be alive or the cut-off date, whichever came first. The results provided below corresponds to descriptive OS information at the time of primary analysis completion date of 09 October 2019.

Time frame:
From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 17 months
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Phase 2: Overall Survival (OS)NA (7.622 to NA)NA (6.801 to NA)12.78 (7.392 to NA)
SecondaryPhase 1 and 2: Plasma Concentration Observed at the End of IV Infusion (Ceoi) of Isatuximab Alone and in Combination With Cemiplimab

Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Ceoi. It was calculated using non-compartmental analysis (NCA) after the first administration in Cycle 1. The PK population was defined independently for isatuximab and cemiplimab and consisted of all participants from the all-treated (AT) population with at least 1 available concentration post-baseline (whatever the cycle and even if dosing was incomplete) with adequate documentation of dosing and sampling dates and times.

Time frame:
At end of infusion (EOI) on Cycle 1 Day 1
Reported as:
Mean · microgram (mcg)/mL
Phase 1 and 2: Plasma Concentration Observed at the End of IV Infusion (Ceoi) of Isatuximab Alone and in Combination With Cemiplimab
microgram (mcg)/mLPhase 2: IsatuximabPhase 1 and 2: Combination Arm: Isatuximab + Cemiplimab
Phase 1 and 2: Plasma Concentration Observed at the End of IV Infusion (Ceoi) of Isatuximab Alone and in Combination With Cemiplimab255 ± 72.1239 ± 67.7
SecondaryPhase 1 and 2: Maximum Observed Concentration (Cmax) of Isatuximab Alone and in Combination With Cemiplimab

Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Cmax. It was calculated using NCA after the first administration in Cycle 1.

Time frame:
At start of infusion (SOI), EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Reported as:
Mean · mcg/mL
Phase 1 and 2: Maximum Observed Concentration (Cmax) of Isatuximab Alone and in Combination With Cemiplimab
mcg/mLPhase 2: IsatuximabPhase 1 and 2: Combination Arm: Isatuximab + Cemiplimab
Phase 1 and 2: Maximum Observed Concentration (Cmax) of Isatuximab Alone and in Combination With Cemiplimab264 ± 68.0247 ± 65.9
SecondaryPhase 1 and 2: Time to Reach Cmax (Tmax) of Isatuximab Alone and in Combination With Cemiplimab

Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of tmax. It was calculated using NCA after the first administration in Cycle 1.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Reported as:
Median · hour
Phase 1 and 2: Time to Reach Cmax (Tmax) of Isatuximab Alone and in Combination With Cemiplimab
hourPhase 2: IsatuximabPhase 1 and 2: Combination Arm: Isatuximab + Cemiplimab
Phase 1 and 2: Time to Reach Cmax (Tmax) of Isatuximab Alone and in Combination With Cemiplimab5.56 (3.25 to 10.50)4.85 (2.58 to 13.70)
SecondaryPhase 1 and 2: Last Concentration Observed Above the Lower Limit of Quantitation (Clast) of Isatuximab Alone and in Combination With Cemiplimab

Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of Clast. It was calculated using NCA after the first administration in Cycle 1.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Reported as:
Mean · mcg/mL
Phase 1 and 2: Last Concentration Observed Above the Lower Limit of Quantitation (Clast) of Isatuximab Alone and in Combination With Cemiplimab
mcg/mLPhase 2: IsatuximabPhase 1 and 2: Combination Arm: Isatuximab + Cemiplimab
Phase 1 and 2: Last Concentration Observed Above the Lower Limit of Quantitation (Clast) of Isatuximab Alone and in Combination With Cemiplimab85.7 ± 44.964.1 ± 32.1
SecondaryPhase 1 and 2: Time of Clast (Tlast) of Isatuximab Alone and in Combination With Cemiplimab

Plasma samples were collected at specified timepoints and those non-impacted by the bioanalytical issue were used for evaluation of tlast. It was calculated using NCA after the first administration in Cycle 1.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Reported as:
Median · hour
Phase 1 and 2: Time of Clast (Tlast) of Isatuximab Alone and in Combination With Cemiplimab
hourPhase 2: IsatuximabPhase 1 and 2: Combination Arm: Isatuximab + Cemiplimab
Phase 1 and 2: Time of Clast (Tlast) of Isatuximab Alone and in Combination With Cemiplimab155.00 (72.40 to 169.00)165.00 (70.20 to 239.00)
SecondaryPhase 1 and 2: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUClast) of Isatuximab Alone and in Combination With Cemiplimab

AUClast was defined as the area under the plasma concentration versus time curve from time 0 to real time tlast calculated using the trapezoidal method over the dosing interval after the first administration in Cycle 1.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Reported as:
Mean · (mcg*hour)/mL
Phase 1 and 2: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUClast) of Isatuximab Alone and in Combination With Cemiplimab
(mcg*hour)/mLPhase 2: IsatuximabPhase 1 and 2: Combination Arm: Isatuximab + Cemiplimab
Phase 1 and 2: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Tlast (AUClast) of Isatuximab Alone and in Combination With Cemiplimab21000 ± 722020200 ± 6590
SecondaryPhase 1 and 2: AUC From Time 0 to Week 1 (AUC1week) of Isatuximab Alone and in Combination With Cemiplimab

AUC1week was defined as the area under the plasma concentration versus time curve from time 0 to 1 week post dose calculated using the trapezoidal method over the dosing interval after the first administration in Cycle 1.

Time frame:
At SOI, EOI, EOI+4 hours, 72 hours and 168 hours on Day 1 of Cycle 1
Reported as:
Mean · (mcg*hour)/mL
Phase 1 and 2: AUC From Time 0 to Week 1 (AUC1week) of Isatuximab Alone and in Combination With Cemiplimab
(mcg*hour)/mLPhase 2: IsatuximabPhase 1 and 2: Combination Arm: Isatuximab + Cemiplimab
Phase 1 and 2: AUC From Time 0 to Week 1 (AUC1week) of Isatuximab Alone and in Combination With Cemiplimab23000 ± 725021100 ± 6450
SecondaryPhase 1 and 2: Number of Participants With Anti-Drug Antibodies (ADA) to Isatuximab

ADA responses were categorized as treatment-induced ADA and treatment boosted ADA. Pre-existing ADA was defined as ADA that were present in samples drawn during the pre-treatment period. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. The ADA evaluable population was defined independently for isatuximab and cemiplimab and consisted of all participants from AT population with at least 1 ADA result (negative, positive, or inconclusive) post-baseline.

Time frame:
From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 20 months
Reported as:
Count of participants · Participants
Phase 1 and 2: Number of Participants With Anti-Drug Antibodies (ADA) to Isatuximab
ParticipantsPhase 2: IsatuximabPhase 1 and 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Pre-existing ADA010
Treatment-induced000
Treatment boosted000
SecondaryPhase 1 and 2: Number of Participants With ADA to Cemiplimab

ADA responses were categorized as treatment-induced ADA and treatment boosted ADA. Pre-existing ADA was defined as ADA that were present in samples drawn during the pre-treatment period. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer.

Time frame:
From Cycle 1 Day 1 up to primary analysis completion date of 9 Oct 2019 i.e., up to approximately 20 months
Reported as:
Count of participants · Participants
Phase 1 and 2: Number of Participants With ADA to Cemiplimab
ParticipantsPhase 1 and 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4W
Pre-existing ADA10
Treatment-induced20
Treatment boosted00

Adverse events

Collected over TEAEs were collected from the first dose up to 30 days after the last dose of study treatment, approximately 50 months. All-Cause Mortality was reported for the whole study duration, approximately 62 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Isatuximab+Cemiplimab Q2W1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Phase 2: Isatuximab20/33 (60.6%)17/33 (51.5%)31/33 (93.9%)
Phase 2: Isatuximab + CemiplimabQ2W23/37 (62.2%)17/37 (45.9%)34/37 (91.9%)
Phase 2:Isatuximab + CemiplimabQ4W22/35 (62.9%)21/35 (60%)27/35 (77.1%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventPhase 1: Isatuximab+Cemiplimab Q2WPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2:Isatuximab + CemiplimabQ4W
Back PainMusculoskeletal and connective tissue disorders1/31/330/371/35
PneumoniaInfections and infestations0/32/331/375/35
InfluenzaInfections and infestations0/33/330/370/35
Acute Kidney InjuryRenal and urinary disorders0/33/332/372/35
PyrexiaGeneral disorders0/30/333/370/35
Pulmonary SepsisInfections and infestations0/30/330/372/35
Upper Respiratory Tract InfectionInfections and infestations0/31/330/372/35
Disease ProgressionGeneral disorders0/31/331/372/35
Infusion Related ReactionInjury, poisoning and procedural complications0/30/330/372/35
Septic ShockInfections and infestations0/30/332/371/35
Most frequent other events
Showing 10 of 68
Most frequent other events
EventPhase 1: Isatuximab+Cemiplimab Q2WPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2:Isatuximab + CemiplimabQ4W
Infusion Related ReactionInjury, poisoning and procedural complications2/318/3315/3715/35
PneumoniaInfections and infestations1/31/332/372/35
SinusitisInfections and infestations1/30/333/370/35
Upper Respiratory Tract InfectionInfections and infestations1/34/334/377/35
Decreased AppetiteMetabolism and nutrition disorders1/33/334/372/35
LethargyNervous system disorders1/30/330/370/35
NeuralgiaNervous system disorders1/30/331/370/35
CoughRespiratory, thoracic and mediastinal disorders1/35/335/372/35
DysphoniaRespiratory, thoracic and mediastinal disorders1/30/330/371/35
Dyspnoea ExertionalRespiratory, thoracic and mediastinal disorders1/31/331/370/35

Baseline characteristics

Phase 1:The Safety population: All screened participants who received at least 1 dose or a part of a dose of study treatments (isatuximab or cemiplimab), regardless of the amount of treatment administered. Phase 2: The Randomized population: All participants who gave informed consent, were assigned randomization number by interactive response technology (IRT), regardless of whether they received any study treatment or received a different study treatment from which they were randomized.

Age, Continuous
Age, Continuous(years)Phase 1: Isatuximab + CemiplimabQ2WPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4WTotal
Mean64.7 ± 2.966.1 ± 9.363.7 ± 10.066.4 ± 9.265.4 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Isatuximab + CemiplimabQ2WPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4WTotal
Female116141647
Male218222062
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Isatuximab + CemiplimabQ2WPhase 2: IsatuximabPhase 2: Isatuximab + CemiplimabQ2WPhase 2: Isatuximab + CemiplimabQ4WTotal
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American02338
White329302991
More than one race00000
Unknown or Not Reported03339
08

Study locations

30 sites
  • University of Colorado-Site Number:8400001
    Denver, Colorado 80262, United States
  • University of Kansas Medical Center-Site Number:8400003
    Kansas City, Kansas 66160-7321, United States
  • Memorial Sloan-Kettering Cancer Center-Site Number:8400002
    New York, New York 10021, United States
  • Fox Chase Cancer Center-Site Number:8400004
    Philadelphia, Pennsylvania 19111, United States
  • Investigational Site Number :0360003
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number :0360002
    Richmond, Victoria 3121, Australia
  • Investigational Site Number :0360001
    West Perth, Western Australia 6005, Australia
  • Investigational Site Number :0760003
    Goiania, Goiás 74605-020, Brazil
  • Investigational Site Number :0760001
    Porto Alegre, Rio Grande Do Sul 90110-270, Brazil
  • Investigational Site Number :0760004
    Sao Paulo, São Paulo 01236030, Brazil
  • Investigational Site Number :1240001
    Montreal, Quebec H1T 2M4, Canada
  • Investigational Site Number :1240005
    Montreal, Quebec H4J 1C5, Canada
  • Investigational Site Number :1240003
    Sherbrooke, Quebec J1H 5N4, Canada
  • Investigational Site Number :2030002
    Brno, 62500, Czechia
  • Investigational Site Number :2030003
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number :2030001
    Praha 2, 12808, Czechia
  • Investigational Site Number :2500004
    Lille, 59037, France
  • Investigational Site Number :2500002
    Nantes, 44093, France
  • Investigational Site Number :2500003
    Pierre Benite, 69495, France
  • Investigational Site Number :2500001
    Villejuif, 94800, France
  • Investigational Site Number :3000001
    Athens, 11528, Greece
  • Investigational Site Number :3480002
    Budapest, 1083, Hungary
  • Investigational Site Number :3800005
    Rozzano, Milano 20089, Italy
  • Investigational Site Number :3800003
    Brescia, 25123, Italy
  • Investigational Site Number :3800001
    Torino, 10126, Italy
  • Investigational Site Number :7240003
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number :7240004
    Badalona, Catalunya [Cataluña] 08916, Spain
  • Investigational Site Number :7240002
    Barcelona, Catalunya [Cataluña] 08036, Spain
  • Investigational Site Number :7240005
    Valencia, Valenciana, Comunidad 46017, Spain
  • Investigational Site Number :7240006
    Madrid, 28041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Apr 2023, 61 months.

Results were first posted in Jun 2024, 1 year 2 months after primary completion.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 61 months is close to that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2017
First posted
Jun 21, 2017
StartActual
Feb 21, 2018
Primary completionActual
Apr 5, 2023
CompletionActual
Apr 5, 2023
Results first posted
Jun 14, 2024
Last update
Jun 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03194867
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 21, 2017
Start date
Feb 21, 2018
Primary completion
Apr 5, 2023
Completion
Apr 5, 2023
Results posted
Jun 14, 2024
Last update
Jun 14, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion